Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Probucol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.60 |
| ▸ | HPN | P05981 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 13/20 | 0.52 |
| ▸ | HMGCR | P04035 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probucol SCHEMBL4242709 | 0.80 | ALOX15 (0.75) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4150 | 0.78 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL5143451 | 0.78 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL12042584 | 0.76 | ALOX15 (0.68) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344652 | 0.76 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4620631 | 0.76 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL13847953 | 0.75 | VCAM1 (0.66) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344272 | 0.73 | HPN (0.81) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL646775 | 0.73 | ALOX15 (0.68) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL8212308 | 0.71 | VCAM1 (0.80) | ALOX15HPNMAPTSIRT5VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176511-A1 | Compositions and methods for treating cardiovascular disorders | HEART RESEARCH INSTITUTE LIMITED, THE (AU) | 2003-09-18 | — | — | US | disclosed |
| EP-1303264-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS | THE HEART RESEARCH INSTITUTE LIMITED (AU) | 2003-04-23 | — | — | EP | disclosed |
| US-20020115728-A1 | Compositions and methods for treating cardiovascular disorders | HEART RESEARCH INSTITUTE, THE (AU) | 2002-08-22 | — | — | US | disclosed |
| WO-2002004031-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS | THE HEART RESEARCH INSTITUTE LIMITED (AU) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176511-A1 | Compositions and methods for treating cardiovascular disorders | LIPG, APOB, LDLR | ALOX15 143/4885HPN 1085/4885MAPT 3457/4885 |
| US-20020115728-A1 | Compositions and methods for treating cardiovascular disorders | LIPG, VEGFA, PCSK9 | ALOX15 420/4885HPN 874/4885MAPT 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.